Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Mar;105(3):414-419.
doi: 10.1136/bjophthalmol-2020-315984. Epub 2020 May 27.

Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study

Sam E Mansour  1   2 , Daniel F Kiernan  3 , Daniel B Roth  4 , David Eichenbaum  5   6 , Nancy M Holekamp  7 , Samer Kaba  8 , Erica Werts  8
Affiliations
Observational Study

Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study

Sam E Mansour et al. Br J Ophthalmol. 2021 Mar.

Abstract

Background: The 0.2 µg/day fluocinolone acetonide (FAc) implant delivers continuous, low-dose, intravitreal corticosteroid for the treatment of diabetic macular oedema (DMO). This ongoing, 3-year, observational clinical trial provides long-term, 'real-world' safety results for the FAc implant in DMO.

Methods: This 24-month interim analysis of a prospective, observational study investigated patients with DMO receiving the commercially available intravitreal 0.2 µg/day FAc implant. The primary outcome was incidence of intraocular pressure (IOP)-lowering procedures. Other IOP-related signals and their relationship to previous corticosteroid exposure, best-corrected visual acuity, central subfield thickness (CST), ocular adverse events and frequency of other treatments were also measured.

Results: Data were collected from 95 previously steroid-challenged patients (115 study eyes) for up to 36 months pre-FAc and 24 months post-FAc implant. Mean IOP for the overall population remained stable post-FAc compared with pre-FAc implant. IOP-related procedures remained infrequent (two IOP-lowering surgeries pre-FAc; two trabeculoplasties and four IOP-lowering surgeries post-FAc). Mean visual acuity was stable post-FAc (mean improvement of 1-3 letters) and fewer DMO treatments were required per year following FAc implant. Mean CST was significantly reduced at 24 months post-FAc implant (p<0.001) and the percentage of patients with CST ≤300 µm was significantly increased (p=0.041).

Conclusion: Few IOP-related procedures were reported during the 24 months post-FAc implant. Positive efficacy outcomes were noted after treatment, with stabilisation of vision and reduction in inflammation, demonstrated by CST. The FAc implant has a favourable benefit-risk profile in the management of DMO, especially when administered after a prior steroid challenge.

Trial registration number: NCT02424019.

Keywords: inflammation; intraocular pressure; macula; retina; treatment other.

PubMed Disclaimer

Conflict of interest statement

Competing interests: SEM has received clinical trial research funds from Alimera Sciences, Chengdu Kanghong Biotechnology, Clearside Biomedical and Genentech. DFK has received research support from Adverum, Alimera Sciences, Allergan, EyePoint and Graybug Pharmaceuticals, received consultant fees from Adverum, Alimera Sciences, Allergan, BVI, EyePoint, Genentech, Mallinckrodt, Notal Vision, Novartis, Physician Recommended Neutriceuticals and Regeneron, and participated in speakers bureau for Alimera Sciences, Allergan, EyePoint, Genentech, Mallinckrodt, Notal Vision, Physician Recommended Neutriceuticals, Regeneron and Spark Therapeutics. DBR has received personal fees from Alimera Sciences, Allergan and Genentech. DE has received personal fees from Alimera Sciences, Allergan, Clearside, EyePoint, Genentech, Gyroscope, Kodiak, Network Eye, Notal Vision, Novartis and Regeneron, received research support from Alimera Sciences, Allergan, Chengdu, Clearside, DORC, Genentech, Gyroscope, Kodiak NGM, Mylan, Network Eye, Novartis, Ophthotech, Ophthea and Recens Medical and received equity from Boston Image Reading Center, Hemera Biopharmaceuticals and US Retina. NMH has received research support from Gemini, Gyroscope, Roche and Genentech, received consultant fees from Acucela, Alimera Sciences, Allegro, Allergan, Clearside, Genentech, Katalyst, Lineage Cell Therapeutics, Notal Vision, Novartis, Regeneron, and Spark, and has patents and stock ownership with Katalyst. SK and EW are employees of Alimera Sciences.

Figures

Figure 1
Figure 1
(A) The mean intraocular pressure (IOP) (SD) over time pre-fluocinolone acetonide (FAc) and post-FAc and (B) best-corrected visual acuity (BCVA) post-FAc in patients with baseline BCVA ≥20/40 and BCVA <20/40.
Figure 2
Figure 2
Treatment frequency shift data assessed by (A) yearly treatment frequency shift and (B) time to rescue treatments. FAc, fluocinolone acetonide.
Figure 3
Figure 3
Central subfield thickness (CST) outcomes in 113 eyes measured by (A) mean CST pre-fluocinolone acetonide (FAc) and post-FAc implant, (B) the percentage of eyes with CST ≤300 µm (SE) at baseline and 24 months post-FAc implant and (C) mean retinal thickness amplitude (RTA) of CST (SE) pre-FAc and post-FAc implant. *p<0.001, †p=0.013, ‡p=0.041.
See this image and copyright information in PMC

References

    1. Yau JWY, Rogers SL, Kawasaki R, et al. . Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012;35:556–64. 10.2337/dc11-1909 - DOI - PMC - PubMed
    1. Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci 2018;19:E942. 10.3390/ijms19040942 - DOI - PMC - PubMed
    1. Solomon SD, Chew E, Duh EJ, et al. . Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes Care 2017;40:412–8. 10.2337/dc16-2641 - DOI - PMC - PubMed
    1. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, et al. . Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010;117:1064–77. 10.1016/j.ophtha.2010.02.031 - DOI - PMC - PubMed
    1. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. . The DA VINCI study: phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema. Ophthalmology 2011;118:1819–26. 10.1016/j.ophtha.2011.02.018 - DOI - PubMed

Publication types

MeSH terms

Associated data